2 results match your criteria: "The Division of General Medical Sciences-Oncology Case Western Reserve University[Affiliation]"
Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism.
Curr Res Pharmacol Drug Discov
July 2022
Case Comprehensive Cancer Center Research Laboratories, The Division of General Medical Sciences-Oncology Case Western Reserve University, Cleveland, OH, 44106, USA.
The mammalian target of rapamycin (mTOR) plays an important role in the aggressiveness and therapeutic resistance of many cancers. Targeting mTOR continues to be under clinical investigation for cancer therapy. Despite the notable clinical success of mTOR inhibitors in extending the overall survival of patients with certain malignancies including metastatic renal cell carcinomas (RCCs), the overall impact of mTOR inhibitors on cancers has been generally disappointing and attributed to various compensatory responses.
View Article and Find Full Text PDFArticle Synopsis
- The cowpea mosaic virus (CPMV) is being tested as an effective immunotherapy for ovarian cancer in mice, showing promising results when given weekly as an in situ vaccine in the intraperitoneal space.
- A new slow-release formulation called CPMV-G4, created by combining CPMV with a dendrimer, allows for a single injection to be as effective as weekly injections of soluble CPMV in reducing tumor size.
- The sustained presence of CPMV in the body after a single CPMV-G4 injection enhances immune response, indicating that viral-dendrimer hybrids could offer a practical solution for longer-lasting cancer treatments.